Efficacy of Infliximab in Patients with Intestinal Behcet's Disease Refractory to Conventional Medication

被引:35
|
作者
Kinoshita, Hiroto [1 ]
Kunisaki, Reiko [1 ]
Yamamoto, Hisae [1 ]
Matsuda, Reikei [1 ]
Sasaki, Tomohiko [1 ]
Kimura, Hideaki [1 ]
Tanaka, Katsuaki [2 ]
Naganuma, Makoto [3 ]
Maeda, Shin [4 ]
机构
[1] Yokohama City Univ, Med Ctr, Ctr Inflammatory Bowel Dis, Yokohama, Kanagawa, Japan
[2] Yokohama City Univ, Med Ctr, Gastroenterol Ctr, Yokohama, Kanagawa, Japan
[3] Keio Univ, Sch Med, Dept Internal Med, Tokyo 108, Japan
[4] Yokohama City Univ, Dept Gastroenterol, Yokohama, Kanagawa, Japan
关键词
fulminant disease; infliximab; infusion interval; intestinal Behcet's disease; prednisolone; tumor necrosis factor-alpha; FACTOR-ALPHA ANTIBODY; CROHNS-DISEASE; SUSCEPTIBILITY LOCI; THERAPY; METAANALYSIS; INVOLVEMENT;
D O I
10.2169/internalmedicine.52.0589
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate the short-and long-term efficacy and safety of infliximab (IFX) in intestinal Behcet's disease (BD) patients in a retrospective cohort study. Methods Among 43 consecutive patients with intestinal BD presenting at the same clinic, 15 with active disease and receiving standard treatment were given IFX infusions (5 mg/kg body weight) every eight weeks. The patients were clinically and endoscopically evaluated before treatment, then assessed after 10 weeks, 12 months and 24 months for a clinical response, defined as a significant improvement in intestinal symptoms and a reduced C-reactive protein (CRP) level. Results At week 10, 12 patients (80%) exhibited a response to IFX, with eight (53%) in remission with no intestinal symptoms and normal CRP levels. A response to IFX was maintained in seven of the 11 patients (64%) available at 12 months and in four of the eight patients (50%) available at 24 months. Of the seven patients receiving prednisolone at entry, five responders had their steroid doses reduced. Fulminant intestinal BD was predictive of an absence of response to IFX. The adverse effects comprised one infusion reaction and one case of fever, most likely related to IFX. Conclusion IFX is effective and safe in patients with refractory intestinal BD.
引用
收藏
页码:1855 / 1862
页数:8
相关论文
共 50 条
  • [21] INFLIXIMAB THERAPY FOR INTESTINAL BEHCET'S DISEASE IN JAPAN
    Takeno, Mitsuhiro
    Nagahori, Masakazu
    Kurosawa, Michiko
    Nagai, Masaki
    Uehara, Ritei
    Ishigatsubo, Yoshiaki
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : S124 - S124
  • [22] Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet's Disease Patients With Uveitis
    Takeno, Mitsuhiro
    Terauchi, Kayo
    Kirino, Yohei
    Yoshimi, Ryusuke
    Mizuki, Nobuhisa
    Shibuya, Etsuko
    Ishigatsubo, Yoshiaki
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S1120 - S1120
  • [23] INFLIXIMAB THERAPY IN PATIENTS WITH REFRACTORY UVEITIS OF BEHCET'S DISEASE: A META-ANALYSIS
    Qin, Y.
    Zhang, X.
    Geng, P.
    Luo, R.
    Zhang, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1103 - 1103
  • [24] Efficacy and Safety of Infliximab in Intestinal Behcet's Disease: A Multicenter, Phase 3 Study (BEGIN)
    Cheon, Jae Hee
    Kim, Hyun-Soo
    Han, Dong Soo
    Kim, Sung Kook
    Shin, Sung Jae
    Kim, Joo Sung
    Ye, Byong Duk
    Song, Geun Am
    Lee, YoungJa
    Kim, Youngdoe
    Lee, Yoosun
    Kim, Won Ho
    GUT AND LIVER, 2023, 17 (05) : 777 - 785
  • [25] USTEKINUMAB EFFICACY IN REFRACTORY BEHCET'S DISEASE
    Costa, L.
    Del Puente, A.
    Foglia, F.
    Benigno, C.
    Bottiglieri, P.
    Girolimetto, N.
    Bascherini, V
    Scotti, N.
    Schiattarella, A.
    Peluso, R.
    Scarpa, R.
    Caso, F.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (06) : S188 - S188
  • [26] Utility of infliximab in the treatment of intestinal lesions in Behcet's disease
    Satoh, S.
    Igarashi, Y.
    Hirano, N.
    Itoh, K.
    Otsuka, T.
    Fujitsuka, Y.
    Shinohara, M.
    Kikuchi, Y.
    Kurakata, H.
    Nagai, H.
    Sumino, Y.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A154 - A154
  • [27] Usefulness of infliximab in the treatment of intestinal lesions in Behcet's disease
    Sato, S.
    Nagai, H.
    Morita, H.
    Hirano, N.
    Kurakata, H.
    Okubo, Y.
    Makino, H.
    Yamamuro, W.
    Igarashi, Y.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 247 - 248
  • [28] The efficacy of infliximab in pediatric patients with steroid-dependent intestinal Behcet's disease: a single center experience in Japan
    Hagiwara, S.
    Kubota, M.
    Nambu, R.
    Kagimoto, S.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S428 - S429
  • [29] Treatment of refractory vitritis in Behcet disease with infliximab
    Uthman, I
    Arayssi, T
    Hamra, R
    Awwad, S
    Kazma, I
    Homaidan, F
    Bashour, Z
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (08) : 1888 - 1888
  • [30] Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Behcet's disease
    Ueda, Sho
    Akahoshi, Mitsuteru
    Takeda, Atsunobu
    Inoue, Yasushi
    Omoto, Aya
    Ayano, Masahiro
    Kimoto, Yasutaka
    Mitoma, Hiroki
    Arinobu, Yojiro
    Niiro, Hiroaki
    Tsukamoto, Hiroshi
    Horiuchi, Takahiko
    Hikita, Shin-Ichi
    Fukuhara, Takako
    Ishibashi, Tatsuro
    Sonoda, Koh-Hei
    Akashi, Koichi
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2018, 5 (01) : 9 - 15